Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function

Kathiresan, Sekar; Gona, Philimon; Larson, Martin G.; Vita, Joseph A.; Mitchell, Gary F.; Tofler, Geoffrey H.; Levy, Daniel; Newton‐Cheh, Christopher; Wang, Thomas J.; Benjamin, Emelia J.; Vasan, Ramachandran S.

doi:10.1161/circulationaha.105.580233

Cited by 82 publications

(55 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The limitations in using plasma biomarkers as indicators of effects at the tissue level must also be noted, as the relationship between plasma markers and tissue actions may be complex. 33 Treatment with either aliskiren or irbesartan monotherapy was well tolerated and not associated with any clinically significant changes in routine blood chemistry and haematologic tests, urinalysis, vital signs or electrocardiogram. The only notable adverse event was headache, which was observed in both treatment groups (more frequently in irbesartan-treated patients).…”

Section: Discussionmentioning

confidence: 86%

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Krone

Hanefeld

Hf³

et al. 2010

J Hum Hypertens

View full text Add to dashboard Cite

Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin-angiotensin-aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/ 7.1 mm Hg after 12 weeks, significantly greater (Pp0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to o135/85 mm Hg (29.2 vs 16.7% with irbesartan; P ¼ 0.019). Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both Po0.001). Aliskiren and irbesartan had similar effects on glucose and lipid profiles and on a panel of biomarkers of inflammation and cardiovascular risk. Both aliskiren and irbesartan were well tolerated. Collectively, these results suggest that aliskiren 300 mg may offer treatment benefits compared with irbesartan 300 mg for BP reduction in patients with hypertension and metabolic syndrome.

show abstract

Section: Discussionmentioning

confidence: 86%

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Krone

Hanefeld

Hf³

et al. 2010

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…Previous studies investigating the relationship between urinary albumin excretion and FMD have yielded conflicting results, with some showing a significant association [27][28][29][30][31] and others showing no such association. [32][33][34] The reasons for these divergent observations are not clear, although methodological differences between various studies could contribute. Further, the inclusion of normotensive individuals in these studies makes direct comparison with the present study difficult.…”

Section: Discussionmentioning

confidence: 99%

Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults

et al. 2007

View full text Add to dashboard Cite

We investigated whether the urinary albumin/creatinine ratio (UACR), a measure of albuminuria, is associated with non-invasive measures of arterial function in hypertensive adults without known coronary heart disease (CHD) or stroke. UACR was measured in the first voided morning urine sample in 469 non-Hispanic white hypertensive individuals (mean age 62.279.8 years, 41% men) belonging to hypertensive sibships. High-resolution ultrasonography of the brachial artery was used to assess flow-mediated dilatation (FMD) -an endothelium-dependent response -and nitroglycerin-mediated dilatation (NMD) -an endothelium-independent response. Because of skewed distribution, UACR was log transformed after addition of 0.1. The association of log (UACR þ 0.1) with FMD and NMD, before and after adjustment for CHD risk factors, serum creatinine, and hypertension medication and statin use was assessed using linear regression analyses. In univariable analyses, variables associated with lower FMD were greater age, male sex, history of smoking, lower high-density lipoprotein (HDL) cholesterol, higher serum creatinine and higher log (UACR þ 0.1); variables associated with lower NMD were greater age, male sex, higher systolic blood pressure, lower HDL cholesterol, higher serum creatinine and higher log (UACR þ 0.1). In separate stepwise multivariable regression analyses that adjusted for conventional CHD risk factors, serum creatinine and hypertension medication and statin use, higher log (UACR þ 0.1) was associated with lower brachial artery FMD (P ¼ 0.035) and NMD (P ¼ 0.0002). These findings highlight the association of increased urinary albumin excretion with impaired vascular reactivity in hypertensive individuals.

show abstract

“…A significant negative correlation between plasma PAI-1 levels and brachial flow-mediated dilatation among healthy volunteers has also been described [16].…”

mentioning

confidence: 86%

The effect of increased dietary fruit and vegetable consumption on endothelial activation, inflammation and oxidative stress in hypertensive volunteers

McCall¹,

McGartland²,

McKinley³

et al. 2011

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function

Cited by 82 publications

References 54 publications

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome

Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults

The effect of increased dietary fruit and vegetable consumption on endothelial activation, inflammation and oxidative stress in hypertensive volunteers

Contact Info

Product

Resources

About